Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently... see more

OTCPK:ARLZQ - Post Discussion

View:
Post by Kisu on Mar 16, 2016 12:21pm

Tribute Results??

So why was this earnings release of Pozen only and later Tribute not advertized from the start.  I was under the impression that the release was to be for the combined companies.  Nicely engineered buying op for those wishing to get into ARZ now that there is finally some volume on the TSX created by the implosion of the stock price.  Will TRX earnings improve the outlook??
Comment by kuatolives on Mar 16, 2016 12:31pm
I was wondering the same thing myself. You have to undesrstand that the vast majority of people in the world are complete morons. On the bright side, when they release Q1 numbers, WOW, look! They more than doubled their revenue! WOWeeeeee!!!
Comment by bunser49 on Mar 16, 2016 1:49pm
I checked with 5i Research and they said TRX will be reporting but didn't have a date. They said the main issue for the price collapse was the combined forecast with revenue of between $48 mil. and $58 mil. range against expectations of $55 mil. They also sited that it is a basically unknown stock and is also suffering from the Valiant effect.. They would rate it as a hold. Anyone on board ...more  
Comment by snootchybootchy on Mar 16, 2016 2:12pm
I personally voted against the deal but in Mr. Harris' defence, there wasn't such strong market sentiment against spec pharma companies when he made the deal.  And the share price more than doubled shortly after the merger announcement.  I should have sold off some of my holdings then but that's on me, not Mr. Harris.
Comment by kuatolives on Mar 16, 2016 2:13pm
As much as I'd like to wave the I told you so flag - I never wanted the merger to go through but resigned myself that it would - it really doesn't help to blame Harris and Co anymore because what's in the past is in the past. But no, they wanted to cash out and couldn't have cared less about their shareholders.  There's an old investment saying "You can go broke being ...more  
Comment by GoldenDilemma on Mar 16, 2016 3:39pm
Yes, knee-jerk reactions and emotional sentiment will be the culprit for any investor. I am with you on this one - hold till the Yosprala party begings. I do believe 2016 may not be our year, but 2017 onwards for the gravy train. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities